Dr. Darren Neil Seril, MD, PhD

Dr. Seril practices at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health.

Dr. Seril's NPI, 1174728679, was assigned on June 15, 2007. Dr. Seril holds New Jersey license 25MA08789900.

Dr. Seril's primary practice is Robert Wood Johnson University Hospital, at One Robert Wood Johnson Place, New Brunswick, NJ 08901 in Middlesex County. The practice phone is (732) 828-3000. Dr. Seril also practices at Robert Wood Johnson University Hospital - New Brunswick, 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901.

Dr. Seril's primary practice is Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health. Dr. Seril is also affiliated with Robert Wood Johnson University Hospital Somerset. The medical group on file is Rutgers-RWJ Scleroderma Program. Dmand AI also links Dr. Seril to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Seril practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Seril's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Seril is board certified in gastroenterology by the American Board of Internal Medicine. Dr. Seril is licensed in New Jersey.

CMS data shows 353 Medicare services from Dr. Seril across 7 procedure codes in 2024, for 233 Medicare patients. Medicare paid $41,949 for them.

CMS counts 233 Medicare patients who saw Dr. Seril in 2024. The largest group is 65 to 74, with 111 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Seril's median patient age at 58, with 48% women.

In 2024, Dr. Seril wrote 859 Medicare Part D claims for 151 patients. 73% of them were for generic drugs. CMS names the drug for 676 of them, across 18 drugs with 11 or more claims each, at $2,313,488 in total drug cost. In 2023, CMS named 711 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Seril for performance year 2024, reported as part of a group. Dr. Seril accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Seril as offering telehealth. CMS counts 60 procedures of colonoscopy by Dr. Seril, more than 67% of the clinicians it reports for that procedure.

Dmand AI links Dr. Seril to 1 clinical trial. Conditions studied include Colitis, Ulcerative and Colitis. Open Payments lists research payments to Dr. Seril that name 1 trial.

CMS Open Payments shows 12 general payments to Dr. Seril from 5 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 78% of the total. Abbvie Inc. paid the most, $1,897. It also lists 5 research payments totaling $829 from 2018 to 2019, naming 1 clinical trial.